Masakiyo Hosokawa

List of Publications by Year
in descending order

80 papers	5,030 citations	136950 32 h-index	95266 68 g-index
83 all docs	83 docs citations	83 times ranked	3919 citing authors

#	Article	IF	Citations
1	THE MAMMALIAN CARBOXYLESTERASES: From Molecules to Functions. Annual Review of Pharmacology and Toxicology, 1998, 38, 257-288.	9.4	690
2	Structure, function and regulation of carboxylesterases. Chemico-Biological Interactions, 2006, 162, 195-211.	4.0	425
3	Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenetics and Genomics, 2005, 15, 513-522.	1.5	339
4	Structure and Catalytic Properties of Carboxylesterase Isozymes Involved in Metabolic Activation of Prodrugs. Molecules, 2008, 13, 412-431.	3.8	326
5	Structure, Function, and Regulation of Carboxylesterases. , 2006, , 219-231.		280
6	Substrate Specificity of Carboxylesterase Isozymes and Their Contribution to Hydrolase Activity in Human Liver and Small Intestine. Drug Metabolism and Disposition, 2006, 34, 1734-1741.	3.3	233
7	Characterization of molecular species of liver microsomal carboxylesterases of several animal species and humans. Archives of Biochemistry and Biophysics, 1990, 277, 219-227.	3.0	176
8	Metabolic Activation of CPT-11, 7-Ethyl-10-(4-(1-piperidino)-1-piperidino)carbonyloxycamptothecin, a Novel Antitumor Agent, by Carboxylesterase.. Biological and Pharmaceutical Bulletin, 1994, 17, 662-664.	1.4	171
9	Recommended nomenclature for five mammalian carboxylesterase gene families: human, mouse, and rat genes and proteins. Mammalian Genome, 2010, 21, 427-441.	2.2	147
10	Limited Brain Distribution of [3R,4R,5S]-4-Acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate Phosphate (Ro 64-0802), a Pharmacologically Active Form of Oseltamivir, by Active Efflux across the Blood-Brain Barrier Mediated by Organic Anion Transporter 3 (Oat3/Slc22a8) and Multidrug Resistance-Associated Protein 4 (Mrp4/Abcc4). Drug Metabolism and Disposition, 2009, 37, 315-321.	3.3	121
11	The Critical Role of Neutral Cholesterol Ester Hydrolase 1 in Cholesterol Removal From Human Macrophages. Circulation Research, 2010, 107, 1387-1395.	4.5	90
12	Genomic Structure and Transcriptional Regulation of the Rat, Mouse, and Human Carboxylesterase Genes. Drug Metabolism Reviews, 2007, 39, 1-15.	3.6	88
13	A Novel Variant Allele of OATP-C (SLCO1B1) Found in a Japanese Patient with Pravastatin-induced Myopathy. Drug Metabolism and Pharmacokinetics, 2004, 19, 453-455.	2.2	84
14	IDENTIFICATION OF HMG-CoA REDUCTASE INHIBITORS AS ACTIVATORS FOR HUMAN, MOUSE AND RAT CONSTITUTIVE ANDROSTANE RECEPTOR. Drug Metabolism and Disposition, 2005, 33, 924-929.	3.3	68
15	cDNA cloning, characterization and stable expression of novel human brain carboxylesterase. FEBS Letters, 1999, 458, 17-22.	2.8	64
16	Measurement of Carboxylesterase (CES) Activities. Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et Al], 2001, 10, Unit4.7.	1.1	64
17	Differential catalytic properties in metabolism of endogenous and exogenous substrates among CYP3A enzymes expressed in COS-7 cells. Biochimica Et Biophysica Acta - General Subjects, 1998, 1380, 297-304.	2.4	59
18	Molecular aspects of carboxylesterase isoforms in comparison with other esterases. Toxicology Letters, 1995, 82-83, 439-445.	0.8	57

#	Article	IF	Citations
19	CYP3A4 inducible model for in vitro analysis of human drug metabolism using a bioartificial liver. Hepatology, 2003, 37, 665-673.	7.3	53
20	Species-, sex-, and age-dependent urinary excretion of cauxin, a mammalian carboxylesterase. Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology, 2006, 145, 270-277.	1.6	53
21	Human CYP2A6 activation of 4-(methylnitrosamino)-l-(3-pyridyl)-1-butanone (NNK): mutational specificity in the gpt gene of AS52 cells. Carcinogenesis, 1994, 15, 2859-2866.	2.8	50
22	Allelic expression imbalance of the human CYP3A4 gene and individual phenotypic status. Human Molecular Genetics, 2004, 13, 2959-2969.	2.9	49
23	Structural Organization and Characterization of the Regulatory Element of the Human Carboxylesterase (CES1A1 and CES1A2) genes. Drug Metabolism and Pharmacokinetics, 2008, 23, 73-84.	2.2	49
24	Functional polymorphisms in carboxylesterase1A2 (CES1A2) gene involves specific protein 1 (Sp1) binding sites. Biochemical and Biophysical Research Communications, 2008, 369, 939-942.	2.1	44
25	Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients. British Journal of Clinical Pharmacology, 2010, 70, 222-233.	2.4	44
26	Purification, molecular cloning, and functional expression of inducible liver acylcarnitine hydrolase in C57BL/6 mouse, belonging to the carboxylesterase multigene family. Archives of Biochemistry and Biophysics, 2003, 416, 101-109.	3.0	40
27	Dexamethasone-induced methylprednisolone hemisuccinate hydrolase: Its identification as a member of the rat carboxylesterase 2 family and its unique existence in plasma. Biochemical Pharmacology, 2005, 69, 1287-1297.	4.4	40
28	Evidence for the Involvement of a Pulmonary First-Pass Effect via Carboxylesterase in the Disposition of a Propranolol Ester Derivative after Intravenous Administration. Journal of Pharmacology and Experimental Therapeutics, 2003, 307, 1234-1242.	2.5	37
29	Hepatocyte nuclear factor-4Î± plays pivotal roles in the regulation of mouse carboxylesterase 2 gene transcription in mouse liver. Archives of Biochemistry and Biophysics, 2006, 447, 107-117.	3.0	37
30	Changes in Carboxylesterase Isoenzymes of Rat Liver Microsomes during Hepatocarcinogenesis. Japanese Journal of Cancer Research, 1991, 82, 800-806.	1.7	36
31	INVOLVEMENT OF HEPATOCYTE NUCLEAR FACTOR 4Î± IN THE DIFFERENT EXPRESSION LEVEL BETWEEN CYP2C9 AND CYP2C19 IN THE HUMAN LIVER. Drug Metabolism and Disposition, 2006, 34, 1012-1018.	3.3	35
32	Retroviral mediated expression of human cytochrome P450 2A6 in C3H/10T1/2 cells confers transformability by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Carcinogenesis, 1993, 14, 1421-1427.	2.8	34
33	Differential responses of rat hepatic microsomal carboxylesterase isozymes to glucocorticoids and pregnenolone 16Î±-carbonitrile. Biochemical Pharmacology, 1993, 45, 2317-2322.	4.4	32
34	Molecular Cloning and Expression of cDNAs Encoding Rat Brain and Liver Cytosolic Long-Chain Acyl-CoA Hydrolases. Biochemical and Biophysical Research Communications, 1997, 232, 198-203.	2.1	30
35	Fawcettimine-Related Alkaloids fromLycopodiumserratum. Journal of Natural Products, 2007, 70, 1024-1028.	3.0	30
36	Synergistic role of specificity proteins and upstream stimulatory factor 1 in transactivation of the mouse carboxylesterase 2/microsomal acylcarnitine hydrolase gene promoter. Biochemical Journal, 2004, 384, 101-110.	3.7	29

#	Article	IF	Citations
37	Prodrug approach using carboxylesterases activity: catalytic properties and gene regulation of carboxylesterase in mammalian tissue. Journal of Pesticide Sciences, 2010, 35, 229-239.	1.4	29
38	The effect of carboxylesterase 1 (CES1) polymorphisms on the pharmacokinetics of oseltamivir in humans. European Journal of Clinical Pharmacology, 2013, 69, 21-30.	1.9	29
39	Purification, Molecular Cloning, and Functional Expression of Dog Liver Microsomal acyl-CoA Hydrolase: A Member of the Carboxylesterase Multigene Family. Archives of Biochemistry and Biophysics, 2001, 389, 245-253.	3.0	26
40	KEY STRUCTURAL FEATURES OF LIGANDS FOR ACTIVATION OF HUMAN PREGNANE X RECEPTOR. Drug Metabolism and Disposition, 2004, 32, 468-472.	3.3	26
41	Carboxylesterases: structure, function and polymorphism in mammals. Journal of Pesticide Sciences, 2010, 35, 218-228.	1.4	26
42	Synthesis of a new class of camptothecin derivatives, the long-chain fatty acid esters of 10-hydroxycamptothecin, as a potent prodrug candidate, and their in vitro metabolic conversion by carboxylesterases. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 415-418.	2.2	25
43	Inactivation of Rat Cytochrome P450 2D Enzyme by a Further Metabolite of 4-Hydroxypropranolol, the Major and Active Metabolite of Propranolol.. Biological and Pharmaceutical Bulletin, 2001, 24, 988-994.	1.4	25
44	IDENTIFICATION OF DI-(2-ETHYLHEXYL) PHTHALATE-INDUCED CARBOXYLESTERASE 1 IN C57BL/6 MOUSE LIVER MICROSOMES: PURIFICATION, CDNA CLONING, AND BACULOVIRUS-MEDIATED EXPRESSION. Drug Metabolism and Disposition, 2004, 32, 1170-1177.	3.3	25
45	Indole-3-propionic acid has chemical chaperone activity and suppresses endoplasmic reticulum stress-induced neuronal cell death. Biochemical and Biophysical Research Communications, 2019, 517, 623-628.	2.1	24
46	cDNA Cloning and Genomic Organization of Peroxisome Proliferator-Inducible Long-Chain Acyl-CoA Hydrolase from Rat Liver Cytosol. Biochemical and Biophysical Research Communications, 1998, 248, 608-612.	2.1	23
47	Toxicological significance in the cleavage of esterase-Î²-glucuronidase complex in liver microsomes by organophosphorus compounds. Chemico-Biological Interactions, 1999, 119-120, 471-478.	4.0	23
48	Differences in the Induction of Carboxylesterase RL4 in Rat Liver Microsomes by Various Perfluorinated Fatty Acids, Metabolically Inert Derivatives of Fatty Acids.. Biological and Pharmaceutical Bulletin, 1996, 19, 765-767.	1.4	21
49	Functional analysis of carboxylesterase in human induced pluripotent stem cell-derived enterocytes. Biochemical and Biophysical Research Communications, 2017, 486, 143-148.	2.1	20
50	Carboxylesterases: Structure, Function and Polymorphism. Biomolecules and Therapeutics, 2009, 17, 335-347.	2.4	19
51	Virtual Clinical Studies to Examine the Probability Distribution of the AUC at Target Tissues Using Physiologically-Based Pharmacokinetic Modeling: Application to Analyses of the Effect of Genetic Polymorphism of Enzymes and Transporters on Irinotecan Induced Side Effects. Pharmaceutical Research, 2017, 34, 1584-1600.	3.5	18
52	Chemical synthesis of an indomethacin ester prodrug and its metabolic activation by human carboxylesterase 1. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 997-1000.	2.2	18
53	Analysis of a child who developed abnormal neuropsychiatric symptoms after administration of oseltamivir: a case report. BMC Neurology, 2015, 15, 130.	1.8	15
54	Synthesis and evaluation of atorvastatin esters as prodrugs metabolically activated by human carboxylesterases. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 921-923.	2.2	14

#	Article	IF	Citations
55	Systematic Identification and Characterization of Carboxylesterases in Cynomolgus Macaques. Drug Metabolism and Disposition, 2014, 42, 2002-2006.	3.3	13
56	Synthesis and evaluation of haloperidol ester prodrugs metabolically activated by human carboxylesterase. European Journal of Pharmaceutical Sciences, 2019, 132, 125-131.	4.0	11
57	Structure-activity relationship of atorvastatin derivatives for metabolic activation by hydrolases. Xenobiotica, 2020, 50, 261-269.	1.1	11
58	N-Nitrosodiethylamine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced morphological transformation of C3H/10T1/2CL8 cells expressing human cytochrome P450 2A6. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, 1994, 324, 93-102.	1.1	10
59	Effects of G169R and P34S Substitutions Produced by Mutations ofCYP2D6*14on the Functional Properties of CYP2D6 Expressed in V79 Cells. Drug Metabolism and Disposition, 2002, 30, 1201-1205.	3.3	10
60	DNA methylation and its involvement incarboxylesterase 1A1(CES1A1) gene expression. Xenobiotica, 2010, 40, 119-128.	1.1	10
61	High-performance liquid chromatographic analysis of the sulfation of 4-hydroxypropranolol enantiomers by monkey liver cytosol. Chirality, 2001, 13, 140-147.	2.6	9
62	Metabolism of medroxyprogesterone acetate (MPA) via CYP enzymes in vitro and effect of MPA on bleeding time in female rats in dependence on CYP activity in vivo. Life Sciences, 2003, 73, 3201-3212.	4.3	9
63	Development of a Caco-2 Cell Line Carrying the Human Intestine-Type CES Expression Profile as a Promising Tool for Ester-Containing Drug Permeability Studies. Biological and Pharmaceutical Bulletin, 2018, 41, 697-706.	1.4	9
64	Investigation of the chiral recognition ability of human carboxylesterase 1 using indomethacin esters. Chirality, 2020, 32, 73-80.	2.6	7
65	Isolation and characterization of arylacetamide deacetylase in cynomolgus macaques. Journal of Veterinary Medical Science, 2015, 77, 721-724.	0.9	6
66	Analysis of carboxylesterase 2 transcript variants in cynomolgus macaque liver. Xenobiotica, 2019, 49, 247-255.	1.1	6
67	A New Methodology for Functionalization at the 3-Position of Indoles by a Combination of Boron Lewis Acid with Nitriles. Chemical and Pharmaceutical Bulletin, 2015, 63, 538-545.	1.3	5
68	Design, synthesis and biological evaluation of water-soluble phenytoin prodrugs considering the substrate recognition ability of human carboxylesterase 1. European Journal of Pharmaceutical Sciences, 2020, 152, 105455.	4.0	5
69	Dexamethasone-mediated transcriptional regulation of rat carboxylesterase 2 gene. Xenobiotica, 2012, 42, 614-623.	1.1	4
70	Gly143Glu polymorphism of the human carboxylesterase1 gene in an Asian population. European Journal of Clinical Pharmacology, 2013, 69, 735-736.	1.9	4
71	Effects of steric hindrance and electron density of ester prodrugs on controlling the metabolic activation by human carboxylesterase. Drug Metabolism and Pharmacokinetics, 2021, 38, 100391.	2.2	4
72	Effects of carbamazepine on the first ovulation in gonadotropin-primed immature female rats. British Journal of Pharmacology, 2001, 134, 1328-1334.	5.4	2

#	Article	IF	Citations
73	Enhancement of the Binding of O-Ethyl O-p-Nitrophenyl 3henylphosphonate (EPNoxon) to Microsomal Carboxylesterase by NAD in vitro. The Japanese Journal of Pharmacology, 1985, 37, 39-44.	1.2	1
74	Are Non-human Primates Useful Experimental Animals for Pre-clinical Study?. Drug Metabolism and Pharmacokinetics, 2010, 25, 221-222.	2.2	0
75	Molecular characterization and polymorphisms of butyrylcholinesterase in cynomolgus macaques. Journal of Medical Primatology, 2018, 47, 185-191.	0.6	0
76	Multiplicity and Acylation/Deacylation Capability of Liver Microsomal Carboxyl este rase Isozymes in Several Animal Species and Humans. Drug Metabolism and Pharmacokinetics, 1993, 8, 637-640.	0.0	0
77	CLONING AND EXPRESSION OF cDNA ENCODING CARBOXYLESTERASE ISOZYMES FROM MAMMALS AND HUMANS. Drug Metabolism and Pharmacokinetics, 1995, 10, 138-141.	0.0	0
78	Multiplicity and Species Differences of Carboxylesterase Isozymes in Mammals and Humans.. Drug Metabolism and Pharmacokinetics, 1998, 13, 405-417.	0.0	0
79	Species differences in the substrate specificity of carboxylesterase isozymes in mammals and humans. Drug Metabolism and Pharmacokinetics, 1998, 13, 90-91.	0.0	0
80	Analysis of genetic polymorphism on the promoter region of a human liver carboxylesterase gene. Drug Metabolism and Pharmacokinetics, 1999, 14, 94-95.	0.0	0